# Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

> **NCT07112170** · NA · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 52 (estimated)

## Conditions studied

- Metastatic Melanoma
- OligoProgressive Metastatic Disease

## Interventions

- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT07112170
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2027-07-24
- **Final completion:** 2028-07-24
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07112170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07112170, "Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07112170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*